Roche announced its fourth quarter and full-year results in 2020. The company's sales reached 44.53 billion Swiss francs (US$ 49.53 billion), down 8% year-on-year and down 2% at a fixed exchange rate. It is mentioned in the financial report that the company is stopping a series of cancer, autoimmune and respiratory system candidate drugs that have entered the middle and late trials, including the combination of Akt inhibitor ipatasertib (also known as RG7440) and chemotherapy drugs for HR positive/triple negative breast cancer patients (triple negative breast cancer).
The company is stopping a series of candidate drugs for cancer, autoimmune and respiratory system that have entered the middle and late trials, among which the combination of Akt inhibitor ipatasertib (also known as RG7440) and chemotherapy drugs used for the first-line treatment of HR positive/triple negative breast cancer patients (triple negative breast cancer) has been deleted from the third-phase clinical research line. Jefferies analysts pointed out in a report that it was "unexpected" that the trial of ipatasertib was terminated after the disappointing data of Ipatasertib's treatment of breast cancer was published at the meeting of the European Society of Medical Oncology (EMSO) in 2020. Because after that meeting, ipatasertib has become a pressure in Roche's later R&D pipeline.